-+ 0.00%
-+ 0.00%
-+ 0.00%

GRI Bio FY25 Net Loss $12M

Benzinga·02/04/2026 13:56:20
Listen to the news

GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases today summarized recently reported Full Year 2025 financial results, provided an update on the Company's current cash position and cash runway and summarized key clinical and corporate highlights.

Net loss was $12 million for the year ended December 31, 2025.